Ibrutinib treatment improves T cell number and function in CLL patients

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2017
主題:
Clinical Medicine
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/
https://ncbi.nlm.nih.gov/pubmed/28714866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料